EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Optimizing stimulation parameters for anterior thalamic nuclei deep brain stimulation in epilepsy: A randomized crossover trial

Juan Luis Alcala-Zermeno, Nicholas M Gregg iD, Gamaleldin Osman, Jayawant N Mandrekar, Keith Starnes, Gregory Worrell iD, Brian N Lundstrom iD

Epilepsia · 2025-09 · 66 (9) · 3309-3317

DOI: 10.1111/epi.18479 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 27.05.2025. Verfasst von Juan Luis Alcala-Zermeno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Anterior Thalamic Nuclei, Drug Resistant Epilepsy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The effects of brain stimulation for diseases like epilepsy are delayed, making stimulation optimization difficult. The parameters for anterior thalamic nuclei (ANT) deep brain stimulation (DBS) for focal drug‐resistant epilepsy management are often restricted to those used in the SANTE landmark trial. There is little evidence regarding effective alternatives, and low‐frequency stimulation is typically neglected. We prospectively compare a widely differing stimulation parameter set to typical settings.

Methods

This randomized, modified crossover, open trial compares the efficacy and safety of an alternative set of parameters using continuous low‐frequency stimulation (cLFS) with a longer pulse width (7 Hz, 200 μs, continuous) compared to SANTE's intermittent high‐frequency stimulation (iHFS) with a short pulse width (145 Hz, 90 μs, cycling 1 min on/5 min off). After 3 months on a randomly assigned first set, patients are switched to the other settings, unless seizure‐free. Patients are re‐evaluated after 3 more months, which marks the completion of the trial. After that, they can either remain on the same settings or switch back.

Results

Sixteen patients with a median baseline seizure frequency of 13.8 seizures/month (interquartile range [IQR] = 2.7–22.8) were included in the analysis. At trial completion (median follow‐up = 30 weeks, IQR = 26–35), ANT‐DBS significantly reduced median seizure frequency (62%, IQR = 18–81, Wilcoxon test statistic [ W ] = 99, p = .008). Both iHFS (33%, IQR = 0–65, W = 81, p = .02) and cLFS (73%, IQR = 30–79, W = 105, p = .001) significantly reduced median seizure frequency. cLFS showed improved median seizure frequency reduction compared to iHFS ( W = 63, p = .03) and was not associated with any moderate or severe adverse effects. Significance Results support cLFS for ANT‐DBS as a safe and effective alternative to typical iHFS parameters. Stimulation with widely differing parameter sets may be as effective as or, in some situations, more effective than typical stimulation parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep Brain StimulationAnterior Thalamic NucleiDrug Resistant EpilepsyHumansCross-Over StudiesMaleFemaleAdultMiddle AgedTreatment OutcomeYoung AdultProspective Studies

Stichwörter der Autor:innen

alternative settingscontinuouslow frequencyneuromodulationneurostimulation

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Comprehensive Epilepsy Center, Department of Neurology, Columbia University Medical Center, New York, New York, USA.
  • Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Child and Adolescent Neurology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Nicholas M Gregg, Gregory Worrell, Brian N Lundstrom

Förderung

  • NINDS NIH HHS

Zitieren

APA

Alcala-Zermeno, J. L., Gregg, N. M., Osman, G., Mandrekar, J. N., Starnes, K., Worrell, G., & Lundstrom, B. N. (2025). Optimizing stimulation parameters for anterior thalamic nuclei deep brain stimulation in epilepsy: A randomized crossover trial. Epilepsia, 66(9), 3309-3317. https://doi.org/10.1111/epi.18479

Vancouver

Alcala-Zermeno JL, Gregg NM, Osman G, Mandrekar JN, Starnes K, Worrell G, et al. Optimizing stimulation parameters for anterior thalamic nuclei deep brain stimulation in epilepsy: A randomized crossover trial. Epilepsia. 2025;66(9):3309-3317. doi:10.1111/epi.18479

BibTeX
@article{AlcalaZermeno2025,
  author = {Alcala-Zermeno, Juan Luis and Gregg, Nicholas M and Osman, Gamaleldin and Mandrekar, Jayawant N and Starnes, Keith and Worrell, Gregory and Lundstrom, Brian N},
  title = {Optimizing stimulation parameters for anterior thalamic nuclei deep brain stimulation in epilepsy: A randomized crossover trial},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {9},
  pages = {3309--3317},
  doi = {10.1111/epi.18479}
}
Kostenlos starten →